116 related articles for article (PubMed ID: 27036631)
21. High versus low-dose rate brachytherapy for cervical cancer.
Patankar SS; Tergas AI; Deutsch I; Burke WM; Hou JY; Ananth CV; Huang Y; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2015 Mar; 136(3):534-41. PubMed ID: 25575481
[TBL] [Abstract][Full Text] [Related]
22. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis.
Rossi PJ; Jani AB; Horowitz IR; Johnstone PA
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):134-8. PubMed ID: 17855014
[TBL] [Abstract][Full Text] [Related]
24. Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate.
Kanayama N; Isohashi F; Yoshioka Y; Baek S; Chatani M; Kotsuma T; Tanaka E; Yoshida K; Seo Y; Suzuki O; Mabuchi S; Shiki Y; Tatsumi K; Kimura T; Teshima T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):346-53. PubMed ID: 25614068
[TBL] [Abstract][Full Text] [Related]
25. Definitive radiation therapy for squamous cell carcinoma of the vagina.
Frank SJ; Jhingran A; Levenback C; Eifel PJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):138-47. PubMed ID: 15850914
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit of vaginectomy compared to local tumor excision in women with FIGO stage I and II primary vaginal carcinoma: a SEER study.
Zhou W; Yue Y; Pei D
Arch Gynecol Obstet; 2020 Dec; 302(6):1429-1439. PubMed ID: 32780160
[TBL] [Abstract][Full Text] [Related]
27. [The results of primary radiotherapy in vaginal carcinoma].
Schäfer U; Micke O; Prott FJ; Kügler R; Neff A; Willich N
Strahlenther Onkol; 1997 May; 173(5):272-80. PubMed ID: 9198909
[TBL] [Abstract][Full Text] [Related]
28. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum.
Samant R; Lau B; E C; Le T; Tam T
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):746-50. PubMed ID: 17512130
[TBL] [Abstract][Full Text] [Related]
29. Improved control of primary vaginal tumours by combined external-beam and interstitial radiotherapy.
MacNaught R; Symonds RP; Hole D; Watson ER
Clin Radiol; 1986 Jan; 37(1):29-32. PubMed ID: 3956090
[TBL] [Abstract][Full Text] [Related]
30. Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis.
Ghia AJ; Gonzalez VJ; Tward JD; Stroup AM; Pappas L; Gaffney DK
Int J Gynecol Cancer; 2011 Feb; 21(2):378-84. PubMed ID: 21270620
[TBL] [Abstract][Full Text] [Related]
31. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).
Moureau-Zabotto L; Ortholan C; Hannoun-Levi JM; Teissier E; Cowen D; Salem N; Lemanski C; Ellis S; Resbeut M
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e135-42. PubMed ID: 23195780
[TBL] [Abstract][Full Text] [Related]
32. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract][Full Text] [Related]
33. Treatment of vaginal recurrences in endometrial carcinoma by high-dose-rate brachytherapy.
Sorbe B; Söderström K
Anticancer Res; 2013 Jan; 33(1):241-7. PubMed ID: 23267151
[TBL] [Abstract][Full Text] [Related]
34. Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study.
Han K; Colson-Fearon D; Liu ZA; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):143-153. PubMed ID: 37951548
[TBL] [Abstract][Full Text] [Related]
35. [Outcome with intracavitary high-dose-rate brachytherapy for primary vaginal cancer].
Kong W; Sun J
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):94-6. PubMed ID: 11953073
[TBL] [Abstract][Full Text] [Related]
36. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer.
Sur R; Donde B; Falkson C; Ahmed SN; Levin V; Nag S; Wong R; Jones G
Brachytherapy; 2004; 3(4):191-5. PubMed ID: 15607150
[TBL] [Abstract][Full Text] [Related]
37. Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
Sorbe B; Bohr L; Karlsson L; Bermark B
Int J Oncol; 2010 Feb; 36(2):371-8. PubMed ID: 20043071
[TBL] [Abstract][Full Text] [Related]
38. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
[TBL] [Abstract][Full Text] [Related]
39. Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy.
Pai HH; Souhami L; Clark BG; Roman T
Gynecol Oncol; 1997 Aug; 66(2):300-7. PubMed ID: 9264580
[TBL] [Abstract][Full Text] [Related]
40. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies.
Kasibhatla M; Clough RW; Montana GS; Oleson JR; Light K; Steffey BA; Jones EL
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):398-403. PubMed ID: 16542793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
